MUFG Americas Holdings Corp Decreases Position in Novartis AG (NVS)

Cornelia Mascio
Dicembre 11, 2017

The institutional investor acquired 165,800 shares of the company's stock, valued at approximately $14,234,000.

A number of other hedge funds and other institutional investors have also modified their holdings of NVS. City Holding Co. increased its holdings in Novartis by 4.6% in the second quarter. Howe & Rusling Inc. now owns 1,341 shares of the company's stock valued at $100,000 after buying an additional 882 shares during the period. Gratus Capital LLC increased its stake in Novartis by 2.5% in the third quarter. Sir Capital Management Lp bought 435,792 shares as the company's stock declined 0.40% while stock markets rallied.

Osborne Partners Capital Management Llc decreased its stake in Novartis A G Sponsored Adr (NVS) by 92.01% based on its latest 2017Q2 regulatory filing with the SEC. Harding Loevner LP purchased a new position in shares of Novartis in the second quarter worth about $146,000. Finally, Mosaic Family Wealth LLC boosted its position in shares of Novartis by 6.1% during the second quarter. Gratus Capital LLC now owns 99,569 shares of the company's stock valued at $8,548,000 after acquiring an additional 2,458 shares during the last quarter.

Novartis AG (NYSE NVS) opened at 81.14 on Monday. About 1.05M shares traded. The stock has a market capitalization of $191.94 billion, a price-to-earnings ratio of 30.50 and a beta of 0.76. Novartis AG has a 12-month low of $69.01 and a 12-month high of $86.90. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The firm had revenue of $12.41 billion during the quarter, compared to analysts' expectations of $12.21 billion. During the same quarter last year, the firm earned $1.23 earnings per share. analysts predict that Novartis AG will post 4.75 earnings per share for the current fiscal year. The firm's revenue for the quarter was up 2.4% compared to the same quarter a year ago.

A number of research firms have weighed in on NVS. Finally, Societe Generale upgraded Novartis AG from a "hold" rating to a "buy" rating and lifted their target price for the company from $73.82 to $74.37 in a report on Tuesday, March 7th. TheStreet upgraded Novartis AG from a "c+" rating to a "b" rating in a report on Friday, June 2nd. Leerink Swann raised their price objective on Novartis from $89.00 to $91.00 and gave the stock a "market perform" rating in a research note on Monday, October 23rd. J P Morgan Chase & Co restated a "neutral" rating on shares of Novartis AG in a report on Thursday. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the stock. The company now has a consensus rating of "Hold" and a consensus target price of $85.32. If you are accessing this piece on another site, it was stolen and republished in violation of worldwide copyright & trademark laws.

Novartis AG is a holding company, which provides healthcare solutions.

PAX Global Technology Limited, an investment holding company, engages in the development and sale of electronic funds transfer point-of-sale products, and provision of related services in the PeopleÂ's Republic of China and internationally. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE